http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 04:59:25 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Morgan Stanley analyst Robert Davies lowered the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR33.00) while maintaining a Underweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Mon, 20 Jul 2026 04:59:25 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Morgan Stanley analyst Robert Davies lowered the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR33.00) while maintaining a Underweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Mon, 20 Jul 2026 04:59:25 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Morgan Stanley analyst Robert Davies lowered the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR33.00) while maintaining a Underweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Mon, 20 Jul 2026 04:59:25 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Morgan Stanley analyst Robert Davies lowered the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR33.00) while maintaining a Underweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Mon, 20 Jul 2026 04:59:25 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Citi analyst Veronika Dubajova raised the price target on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR40.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Fri, 17 Jul 2026 04:56:13 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Citi analyst Veronika Dubajova raised the price target on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR40.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Fri, 17 Jul 2026 04:56:13 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Citi analyst Veronika Dubajova raised the price target on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR40.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Fri, 17 Jul 2026 04:56:13 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Citi analyst Veronika Dubajova raised the price target on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR40.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Fri, 17 Jul 2026 04:56:13 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/Intl+Ratings/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/Intl+Ratings/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/New+Coverage/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/New+Coverage/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/New+Coverage/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/New+Coverage/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/Analyst+Comments/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/Analyst+Comments/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/Analyst+Comments/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/Analyst+Comments/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Flexium+Interconnect+%286269%3ATT%29+%28FMS%29+PT+Raised+to+EUR75+at+Citi/26723764.html Citi analyst Jack Chen raised the price target on Flexium Interconnect (6269:TT) (NYSE: FMS) to EUR75.00 (from EUR67.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Flexium+Interconnect+%286269%3ATT%29+%28FMS%29+PT+Raised+to+EUR75+at+Citi/26723764.html Thu, 02 Jul 2026 06:36:09 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Flexium+Interconnect+%286269%3ATT%29+%28FMS%29+PT+Raised+to+EUR75+at+Citi/26723764.html Citi analyst Jack Chen raised the price target on Flexium Interconnect (6269:TT) (NYSE: FMS) to EUR75.00 (from EUR67.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Flexium+Interconnect+%286269%3ATT%29+%28FMS%29+PT+Raised+to+EUR75+at+Citi/26723764.html Thu, 02 Jul 2026 06:36:09 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Flexium+Interconnect+%286269%3ATT%29+%28FMS%29+PT+Raised+to+EUR75+at+Citi/26723764.html Citi analyst Jack Chen raised the price target on Flexium Interconnect (6269:TT) (NYSE: FMS) to EUR75.00 (from EUR67.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Flexium+Interconnect+%286269%3ATT%29+%28FMS%29+PT+Raised+to+EUR75+at+Citi/26723764.html Thu, 02 Jul 2026 06:36:09 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Flexium+Interconnect+%286269%3ATT%29+%28FMS%29+PT+Raised+to+EUR75+at+Citi/26723764.html Citi analyst Jack Chen raised the price target on Flexium Interconnect (6269:TT) (NYSE: FMS) to EUR75.00 (from EUR67.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Flexium+Interconnect+%286269%3ATT%29+%28FMS%29+PT+Raised+to+EUR75+at+Citi/26723764.html Thu, 02 Jul 2026 06:36:09 -0400 FMS http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++Fresenius+Medical+Care++++For%3A+Dec+31/26707787.html si-local-file:///var/storage/secattach/20260629/26707787.html http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++Fresenius+Medical+Care++++For%3A+Dec+31/26707787.html Mon, 29 Jun 2026 17:30:00 -0400 FME FMS O.00276450 http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++Fresenius+Medical+Care++++For%3A+Dec+31/26707787.html si-local-file:///var/storage/secattach/20260629/26707787.html http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++Fresenius+Medical+Care++++For%3A+Dec+31/26707787.html Mon, 29 Jun 2026 17:30:00 -0400 FME FMS O.00276450 http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++Fresenius+Medical+Care++++For%3A+Dec+31/26707787.html si-local-file:///var/storage/secattach/20260629/26707787.html http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++Fresenius+Medical+Care++++For%3A+Dec+31/26707787.html Mon, 29 Jun 2026 17:30:00 -0400 FME FMS O.00276450 http://www.streetinsider.com/Investing/Fresenius+Medical+Care+dips+after+US+proposes+lower+dialysis+reimbursement+rate/26687942.html <p>Investing.com -- Shares in Fresenius Medical Care (ETR:FMEG) fell about 5% Thursday after U.S. health regulator CMS proposed a smaller-than-expected increase to dialysis reimbursement rates and moved to bundle a key drug category into its payment system.</p> <p></p> <p>CMS proposed a 1.1% increase to the base rate for its end-stage renal disease bundle payment, roughly half what investors had anticipated and well below increases seen in prior years.</p> <p>The regulator also proposed including phosphate binders in the bundle from 2027, removing a payment mechanism that had driven strong uptake of Fresenius’s Velphoro drug.</p> <p>UBS analysts said the proposal was "worse than usual" and below the http://www.streetinsider.com/Investing/Fresenius+Medical+Care+dips+after+US+proposes+lower+dialysis+reimbursement+rate/26687942.html Thu, 25 Jun 2026 06:56:46 -0400 FMEG FMS http://www.streetinsider.com/Investing/Fresenius+Medical+Care+dips+after+US+proposes+lower+dialysis+reimbursement+rate/26687942.html <p>Investing.com -- Shares in Fresenius Medical Care (ETR:FMEG) fell about 5% Thursday after U.S. health regulator CMS proposed a smaller-than-expected increase to dialysis reimbursement rates and moved to bundle a key drug category into its payment system.</p> <p></p> <p>CMS proposed a 1.1% increase to the base rate for its end-stage renal disease bundle payment, roughly half what investors had anticipated and well below increases seen in prior years.</p> <p>The regulator also proposed including phosphate binders in the bundle from 2027, removing a payment mechanism that had driven strong uptake of Fresenius’s Velphoro drug.</p> <p>UBS analysts said the proposal was "worse than usual" and below the http://www.streetinsider.com/Investing/Fresenius+Medical+Care+dips+after+US+proposes+lower+dialysis+reimbursement+rate/26687942.html Thu, 25 Jun 2026 06:56:46 -0400 FMEG FMS http://www.streetinsider.com/General+News/Fresenius+Medical+Care+dips+after+US+proposes+lower+dialysis+reimbursement+rate/26687942.html <p>Investing.com -- Shares in Fresenius Medical Care (ETR:FMEG) fell about 5% Thursday after U.S. health regulator CMS proposed a smaller-than-expected increase to dialysis reimbursement rates and moved to bundle a key drug category into its payment system.</p> <p></p> <p>CMS proposed a 1.1% increase to the base rate for its end-stage renal disease bundle payment, roughly half what investors had anticipated and well below increases seen in prior years.</p> <p>The regulator also proposed including phosphate binders in the bundle from 2027, removing a payment mechanism that had driven strong uptake of Fresenius’s Velphoro drug.</p> <p>UBS analysts said the proposal was "worse than usual" and below the http://www.streetinsider.com/General+News/Fresenius+Medical+Care+dips+after+US+proposes+lower+dialysis+reimbursement+rate/26687942.html Thu, 25 Jun 2026 06:56:46 -0400 FMEG FMS http://www.streetinsider.com/General+News/Fresenius+Medical+Care+dips+after+US+proposes+lower+dialysis+reimbursement+rate/26687942.html <p>Investing.com -- Shares in Fresenius Medical Care (ETR:FMEG) fell about 5% Thursday after U.S. health regulator CMS proposed a smaller-than-expected increase to dialysis reimbursement rates and moved to bundle a key drug category into its payment system.</p> <p></p> <p>CMS proposed a 1.1% increase to the base rate for its end-stage renal disease bundle payment, roughly half what investors had anticipated and well below increases seen in prior years.</p> <p>The regulator also proposed including phosphate binders in the bundle from 2027, removing a payment mechanism that had driven strong uptake of Fresenius’s Velphoro drug.</p> <p>UBS analysts said the proposal was "worse than usual" and below the http://www.streetinsider.com/General+News/Fresenius+Medical+Care+dips+after+US+proposes+lower+dialysis+reimbursement+rate/26687942.html Thu, 25 Jun 2026 06:56:46 -0400 FMEG FMS